Robert Yarchoan
American medical researcher
Robert Yarchoan (born 1950) is a medical researcher who played an important role in the development of the first effective drugs for AIDS. He is the Chief of the HIV and AIDS Malignancy Branch in the National Cancer Institute (NCI) and also coordinates HIV/AIDS malignancy research throughout the NCI as director of the Office of HIV and AIDS Malignancy.
Education and career
Yarchoan was raised in Oceanside, New York. He graduated from Amherst College in 1971 with a degree in biophysics and received his M.D. from the Perelman School of Medicine at the University of Pennsylvania in 1975. He completed internship and residency training in internal medicine at the University of Minnesota and subsequently trained in immunology in the Metabolism Branch of the NCI.
After completing his training he joined the laboratory of Dr. Samuel Broder. In 1991 he was appointed to be a Section Chief of the Medicine Branch and in 1996 he named chief of the newly formed HIV and AIDS Malignancy Branch. Dr. Yarchoan was also appointed to be the first director of the NCI Office of HIV and AIDS Malignancy in 2007, which supervises all HIV/AIDS and AIDS malignancy research within the NCI.
Medical and Research Achievements
Along with his colleagues Drs. Samuel Broder and Hiroaki Mitsuya in the National Cancer Institute (NCI), he co-developed the first effective treatments for HIV/AIDS. With his colleagues, he conducted the first clinical trials of zidovudine (AZT), didanosine (ddI), zalcitabine (ddC), and lamivudine (3TC). These trials were the first to demonstrate that administration of anti-retroviral drugs could reverse the declines in CD4 cells and immunologic impairment caused by human immunodeficiency virus (HIV) infection.
The public source identifies “Robert Yarchoan” as american medical researcher. This brief keeps that definition visible, then builds a research path around Robert, Yarchoan and American.
Why this record matters
A short description can identify a subject without explaining its stakes. For “Robert Yarchoan”, the useful work is to connect “american medical researcher” to the records capable of establishing context and consequence.
Chronology provides the most reliable spine for this subject; interpretation should follow only after identities and dates are secure. The source revision retrieved here is dated Jul 4, 2026. The linked authority identifier is Q7351302. The first chronological checks are 1950, 1971, 1975 and 1991.
Later biographies can compress uncertainty and repeat inherited reputations, so apparently settled claims may still require comparison. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Read biographical claims against dates, named institutions and the cited references. Distinguish a subject’s later reputation from evidence produced during their lifetime.
- Establishing names and roles
- Building a first chronology
- Locating cited institutions
Personal papers, civil or court records, institutional files and the scholarship cited by the source.
Three-step research path
- Establish the record: confirm the title “Robert Yarchoan”, its source revision and the description used here.
- Expand the search: follow Robert Yarchoan primary sources, Robert Yarchoan archive and Robert research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Robert Yarchoan”?
- Which primary records establish identity, chronology and institutional ties?
- Which claims depend on a single source or contested interpretation?
Search terms from this dossier
This entry incorporates text from “Robert Yarchoan” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.